Gene Profile Predicts Risk of Bladder Cancer Recurrence
By LabMedica International staff writers Posted on 07 Apr 2014 |
A genomic study has pinpointed several markers that identify bladder cancer patients at risk of recurrence and that may be indicators of overall survival status.
Nearly half of patients with bladder cancer experience recurrences, so reliable predictors of this recurrent phenotype are needed to guide surveillance and treatment. To identify genetic variants that modify bladder cancer prognosis, investigators at Dartmouth Medical School (Lebanon, NH, USA) focused on genes involved in major biological carcinogenesis processes (apoptosis, proliferation, DNA repair, hormone regulation, immune surveillance, and cellular metabolism).
The investigators analyzed genes from 563 bladder cancer patients to identify genetic variants that modify time to bladder cancer recurrence and patient survival. Patients were followed for a median of 5.4 years during which about half of them experienced at least one recurrence.
Results revealed that those patients with variants in the ALDH2 (aldehyde dehydrogenase 2) gene, which encodes an enzyme involved in alcohol metabolism, were likely to experience bladder cancer recurrence shortly after treatment. Time to recurrence was also shorter for patients who had a variant in the VCAM1 (vascular cellular adhesion molecule 1) gene, which encodes a glycoprotein involved in the development of lymphoid tissues, and were treated with immunotherapy. Patients who had noninvasive tumors and a variant in the DNA repair gene XRCC4 tended to live longer than patients who did not have the variant.
“The genetic markers that we found could potentially be useful for individually tailoring surveillance and treatment of bladder cancer patients,” said first author Dr. Angeline S. Andrew, assistant professor of community and family medicine at Dartmouth Medical School.
The study that identified biomarkers linked to bladder cancer recurrence was published in the March 26, 2014, online edition of the journal BJU International.
Related Links:
Dartmouth Medical School
Nearly half of patients with bladder cancer experience recurrences, so reliable predictors of this recurrent phenotype are needed to guide surveillance and treatment. To identify genetic variants that modify bladder cancer prognosis, investigators at Dartmouth Medical School (Lebanon, NH, USA) focused on genes involved in major biological carcinogenesis processes (apoptosis, proliferation, DNA repair, hormone regulation, immune surveillance, and cellular metabolism).
The investigators analyzed genes from 563 bladder cancer patients to identify genetic variants that modify time to bladder cancer recurrence and patient survival. Patients were followed for a median of 5.4 years during which about half of them experienced at least one recurrence.
Results revealed that those patients with variants in the ALDH2 (aldehyde dehydrogenase 2) gene, which encodes an enzyme involved in alcohol metabolism, were likely to experience bladder cancer recurrence shortly after treatment. Time to recurrence was also shorter for patients who had a variant in the VCAM1 (vascular cellular adhesion molecule 1) gene, which encodes a glycoprotein involved in the development of lymphoid tissues, and were treated with immunotherapy. Patients who had noninvasive tumors and a variant in the DNA repair gene XRCC4 tended to live longer than patients who did not have the variant.
“The genetic markers that we found could potentially be useful for individually tailoring surveillance and treatment of bladder cancer patients,” said first author Dr. Angeline S. Andrew, assistant professor of community and family medicine at Dartmouth Medical School.
The study that identified biomarkers linked to bladder cancer recurrence was published in the March 26, 2014, online edition of the journal BJU International.
Related Links:
Dartmouth Medical School
Latest Pathology News
- New Blood Test Device Modeled on Leeches to Help Diagnose Malaria
- Robotic Blood Drawing Device to Revolutionize Sample Collection for Diagnostic Testing
- Use of DICOM Images for Pathology Diagnostics Marks Significant Step towards Standardization
- First of Its Kind Universal Tool to Revolutionize Sample Collection for Diagnostic Tests
- AI-Powered Digital Imaging System to Revolutionize Cancer Diagnosis
- New Mycobacterium Tuberculosis Panel to Support Real-Time Surveillance and Combat Antimicrobial Resistance
- New Method Offers Sustainable Approach to Universal Metabolic Cancer Diagnosis
- Spatial Tissue Analysis Identifies Patterns Associated With Ovarian Cancer Relapse
- Unique Hand-Warming Technology Supports High-Quality Fingertip Blood Sample Collection
- Image-Based AI Shows Promise for Parasite Detection in Digitized Stool Samples
- Deep Learning Powered AI Algorithms Improve Skin Cancer Diagnostic Accuracy
- Microfluidic Device for Cancer Detection Precisely Separates Tumor Entities
- Virtual Skin Biopsy Determines Presence of Cancerous Cells
- AI Detects Viable Tumor Cells for Accurate Bone Cancer Prognoses Post Chemotherapy
- First Ever Technique Identifies Single Cancer Cells in Blood for Targeted Treatments
- Innovative Blood Collection Device Overcomes Common Obstacles Related to Phlebotomy